Your browser doesn't support javascript.
loading
The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome.
Longbrake, Erin E; Hua, Le H; Mowry, Ellen M; Gauthier, Susan A; Alvarez, Enrique; Cross, Anne H; Pei, Jinglan; Priest, Jessica; Raposo, Catarina; Hafler, David A; Winger, Ryan C.
Afiliação
  • Longbrake EE; Department of Neurology, Yale School of Medicine, New Haven, CT. Electronic address: erin.longbrake@yale.edu.
  • Hua LH; Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV.
  • Mowry EM; The Johns Hopkins University School of Medicine, Baltimore, MD.
  • Gauthier SA; Weill Cornell Medical College, New York, NY.
  • Alvarez E; Rocky Mountain Multiple Sclerosis Center at Anschutz Medical Campus, University of Colorado, Aurora, CO.
  • Cross AH; Washington University School of Medicine, St Louis, MO.
  • Pei J; Genentech, Inc., South San Francisco, CA.
  • Priest J; Genentech, Inc., South San Francisco, CA.
  • Raposo C; Genentech, Inc., South San Francisco, CA.
  • Hafler DA; Department of Neurology, Yale School of Medicine, New Haven, CT.
  • Winger RC; Genentech, Inc., South San Francisco, CA.
Mult Scler Relat Disord ; 68: 104143, 2022 Dec.
Article em En | MEDLINE | ID: mdl-36031693

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Doenças Desmielinizantes / Esclerose Múltipla Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Mult Scler Relat Disord Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Doenças Desmielinizantes / Esclerose Múltipla Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Mult Scler Relat Disord Ano de publicação: 2022 Tipo de documento: Article